	US 12,251,409 B2
	Use of cyanobacterial biomass in treating hepatitis B virus infection
Chuang-Chun Chiuh, Taipei (TW); Yi-Hsiang Chen, Taipei (TW); Ming-Shun Wu, Taipei (TW); and Chun-Wei Cheh, Taipei (TW)
Assigned to FAR EAST BIO-TEC CO., LTD., Taipei (TW)
Filed by FAR EAST BIO-TEC CO., LTD., Taipei (TW)
Filed on May 15, 2020, as Appl. No. 16/875,474.
Application 16/875,474 is a continuation of application No. PCT/US2018/061613, filed on Nov. 16, 2018.
Claims priority of provisional application 62/587,488, filed on Nov. 17, 2017.
Prior Publication US 2020/0276251 A1, Sep. 3, 2020
Int. Cl. A61K 35/748 (2015.01); A61K 9/20 (2006.01); A61K 38/21 (2006.01); A61K 45/06 (2006.01); A61P 1/16 (2006.01); A61P 43/00 (2006.01)

CPC A61K 35/748 (2013.01) [A61K 9/2095 (2013.01); A61K 38/212 (2013.01); A61P 1/16 (2018.01); A61P 43/00 (2018.01); A61K 45/06 (2013.01)]

8 Claims

1. A method for reducing the level of the surface antigen of hepatitis B virus (HBsAg) detectable in a subject suffering from chronic hepatitis B virus (HBV) infection in a subject in need thereof, comprising the step of administering to the subject an effective amount of a cyanobacterial biomass, and the step of administering an effective amount of an antiviral agent, wherein the cyanobacterial biomass is derived from Arthrospira maxima and the cyanobacterial biomass is administered orally at an effective amount of 1 to 20 grams per day for at least three months to result in a decrease of HBsAg level by at least 30%.